scispace - formally typeset

Drug development

About: Drug development is a(n) research topic. Over the lifetime, 12083 publication(s) have been published within this topic receiving 391326 citation(s). more


Open accessJournal ArticleDOI: 10.1038/NRD3028
Abstract: Membrane transporters can be major determinants of the pharmacokinetic, safety and efficacy profiles of drugs. This presents several key questions for drug development, including which transporters are clinically important in drug absorption and disposition, and which in vitro methods are suitable for studying drug interactions with these transporters. In addition, what criteria should trigger follow-up clinical studies, and which clinical studies should be conducted if needed. In this article, we provide the recommendations of the International Transporter Consortium on these issues, and present decision trees that are intended to help guide clinical studies on the currently recognized most important drug transporter interactions. The recommendations are generally intended to support clinical development and filing of a new drug application. Overall, it is advised that the timing of transporter investigations should be driven by efficacy, safety and clinical trial enrolment questions (for example, exclusion and inclusion criteria), as well as a need for further understanding of the absorption, distribution, metabolism and excretion properties of the drug molecule, and information required for drug labelling. more

Topics: Drug development (65%), New drug application (58%)

2,602 Citations

Open accessJournal ArticleDOI: 10.1038/SREP42717
03 Mar 2017-Scientific Reports
Abstract: To be effective as a drug, a potent molecule must reach its target in the body in sufficient concentration, and stay there in a bioactive form long enough for the expected biologic events to occur. Drug development involves assessment of absorption, distribution, metabolism and excretion (ADME) increasingly earlier in the discovery process, at a stage when considered compounds are numerous but access to the physical samples is limited. In that context, computer models constitute valid alternatives to experiments. Here, we present the new SwissADME web tool that gives free access to a pool of fast yet robust predictive models for physicochemical properties, pharmacokinetics, drug-likeness and medicinal chemistry friendliness, among which in-house proficient methods such as the BOILED-Egg, iLOGP and Bioavailability Radar. Easy efficient input and interpretation are ensured thanks to a user-friendly interface through the login-free website Specialists, but also nonexpert in cheminformatics or computational chemistry can predict rapidly key parameters for a collection of molecules to support their drug discovery endeavours. more

Topics: Cheminformatics (55%), Drug development (54%)

2,561 Citations

Open accessJournal ArticleDOI: 10.1016/J.BBAGEN.2013.02.008
Abstract: Background Nature has been a source of medicinal products for millennia, with many useful drugs developed from plant sources Following discovery of the penicillins, drug discovery from microbial sources occurred and diving techniques in the 1970s opened the seas Combinatorial chemistry (late 1980s), shifted the focus of drug discovery efforts from Nature to the laboratory bench Scope of Review This review traces natural products drug discovery, outlining important drugs from natural sources that revolutionized treatment of serious diseases It is clear Nature will continue to be a major source of new structural leads, and effective drug development depends on multidisciplinary collaborations Major Conclusions The explosion of genetic information led not only to novel screens, but the genetic techniques permitted the implementation of combinatorial biosynthetic technology and genome mining The knowledge gained has allowed unknown molecules to be identified These novel bioactive structures can be optimized by using combinatorial chemistry generating new drug candidates for many diseases General Significance The advent of genetic techniques that permitted the isolation / expression of biosynthetic cassettes from microbes may well be the new frontier for natural products lead discovery It is now apparent that biodiversity may be much greater in those organisms The numbers of potential species involved in the microbial world are many orders of magnitude greater than those of plants and multi-celled animals Coupling these numbers to the number of currently unexpressed biosynthetic clusters now identified (> 10 per species) the potential of microbial diversity remains essentially untapped more

Topics: Drug development (54%), Drug discovery (52%)

1,944 Citations

Open accessJournal ArticleDOI: 10.1289/EHP.01109S169
Abstract: In this review we describe and discuss several approaches to selecting higher plants as candidates for drug development with the greatest possibility of success. We emphasize the role of information derived from various systems of traditional medicine (ethnomedicine) and its utility for drug discovery purposes. We have identified 122 compounds of defined structure, obtained from only 94 species of plants, that are used globally as drugs and demonstrate that 80% of these have had an ethnomedical use identical or related to the current use of the active elements of the plant. We identify and discuss advantages and disadvantages of using plants as starting points for drug development, specifically those used in traditional medicine. more

Topics: Drug development (55%), Ethnomedicine (52%)

1,821 Citations

Journal ArticleDOI: 10.1038/NRD2445
Paul D. Leeson1, Brian Springthorpe2Institutions (2)
Abstract: The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making. more

Topics: Drug development (59%)

1,769 Citations

No. of papers in the topic in previous years

Top Attributes

Show by:

Topic's top 5 most impactful authors

Shiew-Mei Huang

37 papers, 1.7K citations

Lawrence J. Lesko

18 papers, 1.7K citations

Janet Woodcock

14 papers, 626 citations

Lei Zhang

14 papers, 1.1K citations

Asher Mullard

11 papers, 197 citations

Network Information
Related Topics (5)

26.3K papers, 745.4K citations

86% related
Clinical trial

57.6K papers, 1.8M citations

82% related
Histone deacetylase

9.5K papers, 532.6K citations

81% related

65.8K papers, 3.5M citations

81% related
PI3K/AKT/mTOR pathway

51.2K papers, 2.1M citations

81% related